Does Mounjaro help you stop smoking — and what does the research actually show?

Why researchers started asking the question

The smoking-cessation angle did not emerge from a designed trial. It surfaced in patient-reported data and observational studies examining people already taking semaglutide or other GLP-1 medicines for weight loss or diabetes, some of whom volunteered that their desire to smoke had dropped. Researchers took note because the biology offers a plausible explanation: GLP-1 receptors are expressed not only in the gut and pancreas but in reward-related areas of the brain, including the ventral tegmental area and nucleus accumbens. These are the same circuits implicated in nicotine dependence.

Tirzepatide, the active ingredient in Mounjaro, activates both GLP-1 and GIP receptors. The dual mechanism is what sets it apart from semaglutide, and scientists are interested in whether GIP receptor activity adds anything to the reward-pathway picture. So far that question does not have a definitive answer. The MHRA-approved indication remains weight management alongside a reduced-calorie diet and increased physical activity, details covered thoroughly in the tirzepatide overview. The question of smoking is in early-stage investigation territory, not established medicine.

The NHS has not issued guidance recommending tirzepatide for smoking cessation, and neither NICE nor the MHRA have reviewed it for that purpose. Approved cessation aids in the UK include varenicline, bupropion and nicotine-replacement therapies, and NHS Stop Smoking services remain the most evidence-backed route for most people.

What the preliminary data look like, and how cautiously to read them

A handful of early analyses drew on large electronic health record datasets, finding associations between GLP-1 medicine use and reduced rates of smoking-related outcomes. One set of analyses published in 2024 attracted significant press attention. The problem with retrospective observational data is that people who take weight-loss injections may differ in dozens of unmeasured ways from those who do not (diet motivation, health engagement, socioeconomic factors) making causal conclusions unreliable.

Properly designed randomised controlled trials, in which participants are allocated to tirzepatide or placebo and smoking behaviour is the pre-specified primary outcome, are the standard needed to change clinical guidance. Those trials are in early or planning stages as of mid-2026. Until results emerge, any claim that Mounjaro helps you stop smoking goes beyond what the evidence supports.

That said, the biological hypothesis is credible enough that it is worth your prescriber knowing if you smoke. Tobacco use raises cardiovascular risk, and that factors into the clinical picture the prescriber builds when assessing suitability for any medicine. You can read more about the specific research interest on the dedicated Mounjaro and smoking page, and about the broader tirzepatide smoking-cessation research angle at tirzepatide and smoking cessation.

What Mounjaro is actually prescribed for, and how it works on appetite

Understanding why this question came up at all requires a brief look at what Mounjaro does. As a dual GIP and GLP-1 receptor agonist, it reduces appetite, slows the rate at which the stomach empties, and influences energy regulation. The result in clinical trials was substantial: in SURMOUNT-1, participants on the 15mg dose lost an average of around 20–21% of body weight over 72 weeks, as reported in the New England Journal of Medicine. The NHS medicines page for tirzepatide gives a clear, plain-language summary of the licensed indications and how it is used.

Because the same brain pathways that regulate hunger also regulate other forms of craving, scientists reasoned that appetite suppression might not be food-specific. Some patients taking GLP-1 medicines have self-reported reduced alcohol cravings too, again, observed rather than proven in purpose-built trials. The mechanism behind Mounjaro's weight-loss effect is a useful starting point for understanding why these observations are biologically plausible, even if they are not yet clinically actionable.

For weight management, the licensed eligibility threshold is a BMI of 30 or above, or 27 or above with at least one weight-related condition. Lower thresholds can apply for some ethnic backgrounds under UK guidance. A real prescriber (not an automated screen) assesses each consultation individually, which matters when someone's health picture includes tobacco use alongside excess weight.

The practical question: should smoking factor into your Mounjaro consultation?

Yes. Not because Mounjaro treats nicotine dependence (it does not) but because a thorough clinical assessment covers cardiovascular risk factors, and smoking is one of the most significant of those. If you are considering Mounjaro for weight management and you also smoke, your prescriber needs to know. It will not automatically disqualify you, but it shapes the clinical conversation.

If you are hoping Mounjaro will serve double duty as a quit aid, the honest answer right now is: the science is not there yet. The trials needed to establish that are still running or in planning. NHS Stop Smoking services, available through your GP and many pharmacies, offer interventions with strong evidence behind them. If and when tirzepatide develops a cessation evidence base, guidance will be updated through NICE and the MHRA, and our Mounjaro help page is kept current with practical guidance as the picture evolves; until then, the two goals (weight management and quitting smoking) are worth pursuing in parallel through appropriate routes.

On cost: if you are assessing whether private Mounjaro treatment makes sense for your situation, the Mounjaro prices page sets out the UK private market context honestly. And if you want a broader view of the available weight-loss treatments, the weight-loss overview covers what is currently licensed and how the options differ. Orders placed by midday on a working day (useful to know if you are planning around a busy week or the end of the month) are dispatched the same day once approved.